Nicholas G Zaorsky1, Eric J Lehrer2, Gargi Kothari3, Alexander V Louie4, Shankar Siva5. 1. Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA; Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA. Electronic address: nicholaszaorsky@gmail.com. 2. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: http://www.twitter.com/EricLehrer. 3. Department of Radiation Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. Electronic address: http://www.twitter.com/GargiKothari. 4. Department of Radiation Oncology, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Electronic address: http://www.twitter.com/DrAlexLouie. 5. Department of Radiation Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. Electronic address: http://www.twitter.com/_ShankarSiva.
Abstract
CONTEXT: The use of stereotactic ablative radiotherapy for recurrent and metastatic renal cell carcinoma (RCC) is not yet standard treatment due to uncertainties regarding its efficacy and safety. OBJECTIVE: The objective of the systematic review and meta-analysis was to assess the efficacy and safety of stereotactic radiotherapy for metastatic RCC. EVIDENCE ACQUISITION: A Population, Intervention, Control, Outcome, Study Design (PICOS)/Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)/Meta-analysis of Observational Studies in Epidemiology (MOOSE) protocol was utilized to select studies published during 1998-2019. The primary outcome was 1 year local control and 1 year overall survival; the secondary outcome was Common Terminology Criteria for Adverse Events grade 3-4 toxicity. Weighted random-effect meta-analyses were conducted using the DerSimonian and Laird method, heterogeneity was evaluated using the I2 statistic and Cochran Q test, and the Egger test assessed publication bias. EVIDENCE SYNTHESIS: A total of 265 studies were screened and 28 studies were included. There were 1602 mutually exclusive patients (679 extracranial/923 intracranial) and 3892 lesions (1159 extracranial/2733 intracranial). The median age was 62yr. The median treatment volume was 59.7cc for extracranial (interquartile range: 31.1-71.4) and 2.3cc for intracranial (interquartile range: 1.3-4.3) lesions. Under the random-effect model, the summary effect size for 1-yr local control was 89.1% (95% confidence interval [CI]: 83.6-93.7%, I2=71%) and 90.1% (95% CI: 83.5-95.3%, I2=74%) for extracranial and intracranial disease, respectively. The 1-yr survival rates were 86.8% (95% CI: 62-99.8%, I2=95%) and 49.7% (95% CI: 41.1-58.3%, I2=74%) for extracranial and intracranial disease, respectively. The incidence of any grade 3-4 toxicity was 0.7% (95% CI: 0-2.1%, I2=0%) for extracranial disease and 1.1% (95% CI: 0-7.4%, I2=53%) for intracranial disease. CONCLUSIONS: Stereotactic radiotherapy is safe and efficacious for RCC oligometastases, with local control at 90% and any significant toxicity at 1%, reported at 1yr. Further prospective studies are needed. PATIENT SUMMARY: Stereotactic radiotherapy is safe and effective in treating kidney cancer that has spread to other parts of the body: 90% of cancers do not progress in the treated region and <1% of patients have side effects at 1yr.
CONTEXT: The use of stereotactic ablative radiotherapy for recurrent and metastatic renal cell carcinoma (RCC) is not yet standard treatment due to uncertainties regarding its efficacy and safety. OBJECTIVE: The objective of the systematic review and meta-analysis was to assess the efficacy and safety of stereotactic radiotherapy for metastatic RCC. EVIDENCE ACQUISITION: A Population, Intervention, Control, Outcome, Study Design (PICOS)/Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)/Meta-analysis of Observational Studies in Epidemiology (MOOSE) protocol was utilized to select studies published during 1998-2019. The primary outcome was 1 year local control and 1 year overall survival; the secondary outcome was Common Terminology Criteria for Adverse Events grade 3-4 toxicity. Weighted random-effect meta-analyses were conducted using the DerSimonian and Laird method, heterogeneity was evaluated using the I2 statistic and Cochran Q test, and the Egger test assessed publication bias. EVIDENCE SYNTHESIS: A total of 265 studies were screened and 28 studies were included. There were 1602 mutually exclusive patients (679 extracranial/923 intracranial) and 3892 lesions (1159 extracranial/2733 intracranial). The median age was 62yr. The median treatment volume was 59.7cc for extracranial (interquartile range: 31.1-71.4) and 2.3cc for intracranial (interquartile range: 1.3-4.3) lesions. Under the random-effect model, the summary effect size for 1-yr local control was 89.1% (95% confidence interval [CI]: 83.6-93.7%, I2=71%) and 90.1% (95% CI: 83.5-95.3%, I2=74%) for extracranial and intracranial disease, respectively. The 1-yr survival rates were 86.8% (95% CI: 62-99.8%, I2=95%) and 49.7% (95% CI: 41.1-58.3%, I2=74%) for extracranial and intracranial disease, respectively. The incidence of any grade 3-4 toxicity was 0.7% (95% CI: 0-2.1%, I2=0%) for extracranial disease and 1.1% (95% CI: 0-7.4%, I2=53%) for intracranial disease. CONCLUSIONS: Stereotactic radiotherapy is safe and efficacious for RCC oligometastases, with local control at 90% and any significant toxicity at 1%, reported at 1yr. Further prospective studies are needed. PATIENT SUMMARY: Stereotactic radiotherapy is safe and effective in treating kidney cancer that has spread to other parts of the body: 90% of cancers do not progress in the treated region and <1% of patients have side effects at 1yr.
Authors: G Marvaso; G Corrao; O Oneta; M Pepa; M Zaffaroni; F Corso; S Gandini; A Cecconi; D Zerini; G C Mazzola; M Augugliaro; M Cossu Rocca; E Verri; F Cattani; F La Fauci; L Bergamaschi; S Luzzago; A F Mistretta; G Musi; F Nolè; O De Cobelli; R Orecchia; B A Jereczek-Fossa Journal: Clin Transl Oncol Date: 2021-03-09 Impact factor: 3.405
Authors: Raquibul Hannan; Michael Christensen; Hans Hammers; Alana Christie; Brendan Paulman; Dandan Lin; Aurelie Garant; Waddah Arafat; Kevin Courtney; Isaac Bowman; Suzanne Cole; David Sher; Chul Ahn; Hak Choy; Robert Timmerman; James Brugarolas Journal: Eur Urol Oncol Date: 2022-01-02
Authors: Łukasz Raszewski; Artur J Chyrek; Magdalena Marciniak; Wojciech M Burchardt; Grzegorz M Biele da; Adam Chicheł Journal: J Contemp Brachytherapy Date: 2021-05-07